Ariel Precision Medicine
- Biotech or pharma, therapeutic R&D
Ariel is developing APM-176, a Phase 2 ready NCE which potentiates CFTR (both mutated and wild-type) targeting patients with CFTR mediated chronic conditions such as Chronic rhinosinusitis (CRS), pancreatitis, bronchiectasis and biliary diseases. Our AI fueled genetic segmentation tool enriches clinical trials with appropriate patients, decreasing the trial size requirements while increasing the likelihood of success.
Address
PittsburghPennsylvania
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}